Digital Health & Discovery Platform
@dhdp-ca.bsky.social did:plc:w6uj7tqg2364o3cs23opmtia
We combine Canadian expertise in artificial intelligence (AI) and precision medicine to improve healthcare for Canadians. www.dhdp.ca Led by the Terry Fox Research Institute @terryfoxresearch.bsky.social
Bluesky’a katılma tarihi:
- Takipçi
- 158
- Takip edilen
- 363
- Post
- 407
- Sıralamaya girdiği gün
- 0
Özet
Digital Health & Discovery Platform (@dhdp-ca.bsky.social), 21 Nisan 2025 tarihinde katılan bir Bluesky kullanıcısı. 158 takipçisi var, 363 hesabı takip ediyor ve 407 post paylaştı.
Sıralama geçmişi
Bu hesabın postlarının Debya günlük listesine girdiği en iyi günler.
Bu hesap henüz günlük sıralamaya girmedi.
Son beğendiği postlar
Bluesky ağındaki herkese açık beğeniler.
HAPPENING NOW: Fueling Digital Health Innovation How can a $25M gift accelerate cancer research through AI, machine learning and big data? Charles Crosbie of the Terry Fox Research Institute explores how this investment can advance innovation across Canada’s public and private sectors. #PACT2026
Postu göster🍁 Investing in future precision onocology leaders 🍁 MOHCCN is awarding $2.1 million to four outstanding early-career clinician-scientists through the 2026 Clinician-Scientist Awards. Read the full announcement: www.marathonofhopecancercentres.ca/impact/news-...
Postu gösterIs treatment working? Could it come back? For young people with Hodgkin lymphoma, uncertainty can be overwhelming. Dr. Tomohiro Aoki, a 2026 MOHCCN Clinician-Scientist Awardee, is developing a blood test to monitor treatment response and detect relapse earlier. Learn more: tinyurl.com/eskd7r68
Postu gösterThe immune system is designed to fight disease. So why can some brain tumours evade its attack? Dr. Charles Couturier, a neurosurgeon and researcher at McGill University, is working to find answers with support from a 2026 MOHCCN Clinician-Scientist Award. Learn more: tinyurl.com/5cvr3m5e
Postu gösterHow do we know when a more advanced treatment is the better choice? 2026 MOHCCN Clinician-Scientist Awardee, Dr. Rachel Glicksman will lead the ASPIRE clinical trial to assess whether adaptive SBRT improves patients’ quality of life and if it's cost-effective. Learn more: tinyurl.com/3zwarwen
Postu göster
Blokladığı hesaplar
Bluesky’da bloklar herkese açık kayıtlardır.
Bu hesap kimseyi bloklamıyor.